Runde Biotechnology Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
210
- Latest Deal Type
-
Later Stage VC
- Investors
-
1
Runde Biotechnology General Information
Description
Manufacturer of biological raw materials designed for health-related applications. The company uses microbial fermentation to produce glucosamine, its main products include glucosamine, D-ribose, and special enzymes for extracting traditional Chinese medicine (cellulase, glycosidase, etc.), which can be widely used in biomedicine, health food, beauty and pet food, providing world-leading product solutions for customers in the biomedical industry.
Contact Information
Website
www.rundebio.comCorporate Office
- Number 78 Runde Road, Development Zone, Xintai City
- Tai'an
- Taian, Shandong 271200
- China
Corporate Office
- Number 78 Runde Road, Development Zone, Xintai City
- Tai'an
- Taian, Shandong 271200
- China
Runde Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 15-May-2024 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | 08-Oct-2023 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 16-Dec-2022 | Completed | Generating Revenue | |||
| 2. Secondary Transaction - Private | 17-Feb-2022 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 16-May-2018 | Completed | Generating Revenue |
Runde Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Runde Biotechnology Patents
Runde Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026118467-A1 | Corynebacterium glutamicum for producing n-acetylglucosamine, and use thereof | Pending | 03-Dec-2024 | ||
| WO-2021128465-A1 | Rama transcription factor mutant for promoting production of n-acetylglucosamine and application thereof | Inactive | 26-Dec-2019 | ||
| US-12275763-B2 | Rama transcription factor mutant for promoting production of n-acetylglucosamine and use thereof | Active | 26-Dec-2019 | ||
| US-20220106366-A1 | Rama transcription factor mutant for promoting production of n-acetylglucosamine and use thereof | Active | 26-Dec-2019 | ||
| WO-2021128464-A1 | Transcription factor sugr coding gene and application thereof in production of n-acetylglucosamine | Inactive | 25-Dec-2019 | C12N15/77 |
Runde Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Runde Biotechnology Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Shandong Dongtai Huide Investment | Venture Capital | Minority |
Runde Biotechnology FAQs
-
When was Runde Biotechnology founded?
Runde Biotechnology was founded in 2014.
-
Where is Runde Biotechnology headquartered?
Runde Biotechnology is headquartered in Taian, China.
-
What is the size of Runde Biotechnology?
Runde Biotechnology has 210 total employees.
-
What industry is Runde Biotechnology in?
Runde Biotechnology’s primary industry is Biotechnology.
-
Is Runde Biotechnology a private or public company?
Runde Biotechnology is a Private company.
-
What is Runde Biotechnology’s current revenue?
The current revenue for Runde Biotechnology is .
-
Who are Runde Biotechnology’s investors?
Shandong Dongtai Huide Investment has invested in Runde Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
